吉非替尼治疗既往接受过治疗的晚期非小细胞肺癌患者的多机构随机II期试验
这项随机双盲多中心II期试验纳入210例既往接受过1-2种化疗方案(至少含铂)的晚期非小细胞肺癌患者,随机接受吉非替尼250 mg/d或500 mg/d口服。两剂量组客观缓解率分别为18.4%和19.0%,中位无进展生存期2.7和2.8个月,中位总生存期7.6和8.0个月;250 mg/d组药物相关不良事件导致停药比例更低(1.9% vs 9.4%)。结论认为吉非替尼250 mg/d是既往治疗晚期NSCLC的重要新治疗选择。
要点
- 吉非替尼250 mg/d与500 mg/d两组疗效相似,客观缓解率分别为18.4%和19.0%。
- 250 mg/d组因药物相关不良事件停药比例为1.9%,低于500 mg/d组的9.4%。
- 吉非替尼250 mg/d作为二线或三线治疗显示有临床意义的抗肿瘤活性和症状缓解。
核心结论
- 吉非替尼在既往治疗的晚期非小细胞肺癌患者中作为二线和三线治疗显示出有临床意义的抗肿瘤活性和症状缓解。
- 250 mg/d剂量下吉非替尼具有有利的不良事件特征,是既往治疗晚期NSCLC患者的重要新治疗选择。
研究设计与样本
- 随机、双盲、平行组、多中心II期试验。
- 纳入210例既往接受过1或2种化疗方案(至少一种含铂)的晚期非小细胞肺癌患者,随机接受吉非替尼250 mg或500 mg口服每日一次。
主要发现
- 250 mg/d组和500 mg/d组客观肿瘤缓解率分别为18.4%(95%CI 11.5-27.3)和19.0%(95%CI 12.1-27.9)。
- 可评估患者中,250 mg/d组和500 mg/d组症状改善率分别为40.3%(95%CI 28.5-53.0)和37.0%(95%CI 26.0-49.1)。
- 250 mg/d组和500 mg/d组中位无进展生存期分别为2.7个月和2.8个月,中位总生存期分别为7.6个月和8.0个月。
- 肿瘤缓解患者中,250 mg/d组和500 mg/d组分别有69.2%和85.7%记录到症状改善。
- 两剂量组不良事件大多为轻度(1或2级),主要为皮肤反应和腹泻;药物相关毒性在较高剂量组更频繁,因药物相关不良事件停药的比例在250 mg/d组为1.9%、500 mg/d组为9.4%。
临床怎么用
- 原文结论认为吉非替尼250 mg/d是既往治疗晚期非小细胞肺癌患者的重要新治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: This was a randomized, double-blind, parallel-group, multicenter phase II trial. Two hundred ten patients with advanced NSCLC who were previously treated with one or two chemotherapy regimens (at least one containing platinum) were randomized to receive either 250-mg or 500-mg oral doses of gefitinib once daily. RESULTS: Efficacy was similar for the 250- and 500-mg/d groups. Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively. Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response. Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea. Drug-related toxicities were more frequent in the higher-dose group. Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively. CONCLUSION: Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients. At 250 mg/d, gefitinib had a favorable AE profile. Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
引用
- Fukuoka M, Yano S, Giaccone G, et al. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2023. PMID: 36791474. doi:10.1200/JCO.22.02499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。